Does the media refer more to ABCL or RYTM?

In the previous week, AbCellera Biologics had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 3 mentions for AbCellera Biologics and 1 mentions for Rhythm Pharmaceuticals. AbCellera Biologics' average media sentiment score of 0.64 beat Rhythm Pharmaceuticals' score of 0.60 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABCL or MIRM?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.64 beat Mirum Pharmaceuticals' score of 0.63 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABCL or TGTX?

In the previous week, TG Therapeutics had 11 more articles in the media than AbCellera Biologics. MarketBeat recorded 14 mentions for TG Therapeutics and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.64 beat TG Therapeutics' score of 0.54 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABCL or CNTA?

In the previous week, AbCellera Biologics had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 3 mentions for AbCellera Biologics and 2 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.77 beat AbCellera Biologics' score of 0.64 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABCL or SRRK?

In the previous week, AbCellera Biologics and AbCellera Biologics both had 3 articles in the media. AbCellera Biologics' average media sentiment score of 0.64 beat Scholar Rock's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

AbCellera Biologics (ABCL) Competitors

$5.62 -0.75 (-11.77%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$5.78 +0.16 (+2.90%)

As of 06/5/2026 07:58 PM Eastern

Compare

ABCL vs. RYTM, MIRM, TGTX, CNTA, and SRRK

Should you buy AbCellera Biologics stock or one of its competitors? MarketBeat compares AbCellera Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AbCellera Biologics include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), TG Therapeutics (TGTX), Centessa Pharmaceuticals (CNTA), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

AbCellera Biologics (NASDAQ:ABCL) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

In the previous week, AbCellera Biologics had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 3 mentions for AbCellera Biologics and 1 mentions for Rhythm Pharmaceuticals. AbCellera Biologics' average media sentiment score of 0.64 beat Rhythm Pharmaceuticals' score of 0.60 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AbCellera Biologics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

AbCellera Biologics presently has a consensus price target of $7.80, indicating a potential upside of 38.79%. Rhythm Pharmaceuticals has a consensus price target of $131.81, indicating a potential upside of 52.56%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

AbCellera Biologics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A
Rhythm Pharmaceuticals	$189.76M	31.20	-$196.54M	-$3.13	N/A

Summary

AbCellera Biologics beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

AbCellera Biologics (NASDAQ:ABCL) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

AbCellera Biologics presently has a consensus price target of $7.80, indicating a potential upside of 38.79%. Mirum Pharmaceuticals has a consensus price target of $137.64, indicating a potential upside of 47.24%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.64 beat Mirum Pharmaceuticals' score of 0.63 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a net margin of -140.24% compared to AbCellera Biologics' net margin of -181.75%. Mirum Pharmaceuticals' return on equity of -11.28% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

AbCellera Biologics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A
Mirum Pharmaceuticals	$521.31M	10.93	-$23.36M	-$13.61	N/A

Summary

Mirum Pharmaceuticals beats AbCellera Biologics on 10 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to TG Therapeutics?

AbCellera Biologics (NASDAQ:ABCL) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

TG Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A
TG Therapeutics	$616.29M	9.98	$447.18M	$2.86	14.04

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, TG Therapeutics had 11 more articles in the media than AbCellera Biologics. MarketBeat recorded 14 mentions for TG Therapeutics and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.64 beat TG Therapeutics' score of 0.54 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to AbCellera Biologics' net margin of -181.75%. TG Therapeutics' return on equity of 88.73% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
TG Therapeutics	65.95%	88.73%	43.44%

AbCellera Biologics presently has a consensus target price of $7.80, suggesting a potential upside of 38.79%. TG Therapeutics has a consensus target price of $52.50, suggesting a potential upside of 30.73%. Given AbCellera Biologics' higher probable upside, equities analysts plainly believe AbCellera Biologics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

TG Therapeutics beats AbCellera Biologics on 10 of the 15 factors compared between the two stocks.

How does AbCellera Biologics compare to Centessa Pharmaceuticals?

AbCellera Biologics (NASDAQ:ABCL) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, AbCellera Biologics had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 3 mentions for AbCellera Biologics and 2 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.77 beat AbCellera Biologics' score of 0.64 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AbCellera Biologics presently has a consensus target price of $7.80, indicating a potential upside of 38.79%. Centessa Pharmaceuticals has a consensus target price of $41.33, indicating a potential upside of 4.32%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, equities analysts clearly believe AbCellera Biologics is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Centessa Pharmaceuticals has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

AbCellera Biologics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

AbCellera Biologics has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A
Centessa Pharmaceuticals	$15M	394.17	-$197.53M	-$1.79	N/A

Summary

AbCellera Biologics beats Centessa Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Scholar Rock?

AbCellera Biologics (NASDAQ:ABCL) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, AbCellera Biologics and AbCellera Biologics both had 3 articles in the media. AbCellera Biologics' average media sentiment score of 0.64 beat Scholar Rock's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 13.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AbCellera Biologics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Scholar Rock has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Scholar Rock	N/A	-163.52%	-96.67%

AbCellera Biologics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

AbCellera Biologics presently has a consensus target price of $7.80, suggesting a potential upside of 38.79%. Scholar Rock has a consensus target price of $56.00, suggesting a potential upside of 26.41%. Given AbCellera Biologics' higher probable upside, research analysts plainly believe AbCellera Biologics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Summary

AbCellera Biologics beats Scholar Rock on 10 of the 15 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCL vs. The Competition

Export

Metric	AbCellera Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.35B	$6.47B	$12.42B
Dividend Yield	N/A	2.33%	2.68%	5.33%
P/E Ratio	-11.71	18.85	23.79	23.63
Price / Sales	22.84	307.82	543.15	124.82
Price / Cash	N/A	114.83	42.35	57.17
Price / Book	1.74	6.51	9.73	6.35
Net Income	-$146.41M	$24.15M	$3.57B	$337.59M
7 Day Performance	-8.91%	-6.96%	-1.25%	-2.51%
1 Month Performance	11.51%	-4.27%	0.83%	-0.68%
1 Year Performance	130.33%	36.81%	24.11%	25.37%

AbCellera Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCL AbCellera Biologics	2.7032 of 5 stars	$5.62 -11.8%	$7.80 +38.8%	+137.1%	$1.95B	$75.13M	N/A	500	News Coverage Gap Down
RYTM Rhythm Pharmaceuticals	2.6487 of 5 stars	$87.84 -2.6%	$131.81 +50.1%	+30.6%	$6.02B	$189.76M	N/A	140	Analyst Forecast
MIRM Mirum Pharmaceuticals	3.7567 of 5 stars	$98.62 -2.0%	$137.08 +39.0%	+109.4%	$6.01B	$569.61M	N/A	140	Analyst Forecast Insider Trade
TGTX TG Therapeutics	3.6472 of 5 stars	$38.87 -0.9%	$52.50 +35.1%	+2.2%	$5.95B	$616.29M	13.59	290
CNTA Centessa Pharmaceuticals	2.1449 of 5 stars	$39.75 -0.2%	$40.70 +2.4%	+234.1%	$5.93B	N/A	N/A	200	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCL) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Competitors

ABCL vs. RYTM, MIRM, TGTX, CNTA, and SRRK

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Summary

How does AbCellera Biologics compare to TG Therapeutics?

Summary

How does AbCellera Biologics compare to Centessa Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Competitors

ABCL vs. RYTM, MIRM, TGTX, CNTA, and SRRK

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Is ABCL or RYTM more profitable?

Does the media refer more to ABCL or RYTM?

Do insiders and institutionals believe in ABCL or RYTM?

Which has more risk & volatility, ABCL or RYTM?

Do analysts prefer ABCL or RYTM?

Which has better earnings and valuation, ABCL or RYTM?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Do analysts prefer ABCL or MIRM?

Do institutionals and insiders believe in ABCL or MIRM?

Does the media refer more to ABCL or MIRM?

Is ABCL or MIRM more profitable?

Which has more volatility and risk, ABCL or MIRM?

Which has preferable earnings & valuation, ABCL or MIRM?

Summary

How does AbCellera Biologics compare to TG Therapeutics?

Which has better earnings & valuation, ABCL or TGTX?

Do institutionals and insiders have more ownership in ABCL or TGTX?

Does the media refer more to ABCL or TGTX?

Which has more risk & volatility, ABCL or TGTX?

Is ABCL or TGTX more profitable?

Do analysts prefer ABCL or TGTX?

Summary

How does AbCellera Biologics compare to Centessa Pharmaceuticals?

Does the media favor ABCL or CNTA?

Do insiders & institutionals believe in ABCL or CNTA?

Do analysts recommend ABCL or CNTA?

Is ABCL or CNTA more profitable?

Which has more risk & volatility, ABCL or CNTA?

Which has preferable earnings and valuation, ABCL or CNTA?

Summary

How does AbCellera Biologics compare to Scholar Rock?

Does the media refer more to ABCL or SRRK?

Do insiders and institutionals hold more shares of ABCL or SRRK?

Which has better earnings & valuation, ABCL or SRRK?

Is ABCL or SRRK more profitable?

Which has more risk & volatility, ABCL or SRRK?

Do analysts rate ABCL or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools